Daré Bioscience Announces Publication In Contraception Of Efficacy And Safety Findings From A Pre-Pivotal Postcoital Test Study Of Ovaprene: An Investigational Hormone-Free Monthly Intravaginal Contraceptive
Daré Bioscience Announces Publication In Contraception Of Efficacy And Safety Findings From A Pre-Pivotal Postcoital Test Study Of Ovaprene: An Investigational Hormone-Free Monthly Intravaginal Contraceptive
DaréBioscience宣佈在《避孕》雜誌上發表一項針對Ovaprene的關鍵性交後測試研究的功效和安全性結果：一種研究性無激素的月度陰道內避孕藥
Published data shows that Ovaprene was safe and effective in a postcoital test study of 33 women
已公佈的數據顯示，在一項針對33名女性的性交後測試研究中，Ovaprene是安全有效的
Pivotal Phase 3 contraceptive efficacy clinical study of Ovaprene currently enrolling
Ovaprene的關鍵性3期避孕功效臨床研究目前正在報名
Ovaprene has the potential to be the first FDA-approved hormone-free monthly intravaginal contraceptive for women
Ovaprene有可能成爲美國食品藥品管理局批准的第一種女性每月無激素陰道內避孕藥
SAN DIEGO, April 11, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced the publication of data from the postcoital test clinical study of Ovaprene in two original research articles in the journal Contraception.
聖地亞哥，2024年4月11日（GLOBE NEWSWIRE）——女性健康創新的領導者達瑞生物科學公司（納斯達克股票代碼：DARE）今天宣佈，在該期刊的兩篇原創研究文章中公佈了Ovaprene性交後測試臨床研究的數據 避孕。
Publication Details:
出版物詳情：
Mauck, et al. "Successful postcoital testing of Ovaprene: An investigational non- hormonal monthly vaginal contraceptive...
莫克等人“Ovaprene的成...
登入免費觀看全文
登入/註冊